Orphenadrine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intramuscular, Intravenous
Painful muscle spasm associated with musculoskeletal conditions
Adult: As orphenadrine citrate: 60 mg 12 hourly via IM or slow IV inj.
Elderly: Dose reduction may be required.

Oral
Drug-induced extrapyramidal symptoms, Parkinsonism
Adult: As orphenadrine hydrochloride: Initially, 150 mg daily in divided doses, gradually increase by 50 mg every 2-3 days until maximum benefits is attained. Usual maintenance dose: 150-300 mg daily. Max: 400 mg daily in divided doses.
Elderly: Dose reduction may be required.

Oral
Painful muscle spasm associated with musculoskeletal conditions
Adult: As orphenadrine citrate: 100 mg bid.
Elderly: Dose reduction may be required.
Cách dùng
May be taken with or without food. May be taken w/ meals if GI upset occurs.
Chống chỉ định
Glaucoma, gastrointestinal obstruction (e.g. pyloric or duodenal obstruction), stenosing peptic ulcer, megaoesophagus, prostatic hypertrophy, bladder neck obstruction, myasthenia gravis; tardive dyskinesia (orphenadrine hydrochloride).
Thận trọng
Patient with CV disease (e.g. heart failure, cardiac decompensation, coronary insufficiency, tachycardia, cardiac arrhythmias), thyrotoxicosis, hypertension, history of drug abuse or acute alcoholism, porphyria, micturition difficulties. Avoid abrupt withdrawal. Some products or formulations are not interchangeable; refer to specific product guideline for further information. Renal and hepatic impairment. Elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: CNS depression, euphoria (increased risk for drug abuse and dependence).
Blood and lymphatic system disorders: Very rarely, aplastic anaemia.
Cardiac disorders: Palpitation, tachycardia.
Eye disorders: Disturbance of visual accommodation.
Gastrointestinal disorders: Dry mouth, gastrointestinal disturbances, nausea, constipation.
Immune system disorders: Hypersensitivity reaction. Rarely, anaphylaxis (IM).
Nervous system disorders: Dizziness, drowsiness, restlessness.
Psychiatric disorders: Confusion, hallucination.
Renal and urinary disorders: Micturition difficulties.
IM/IV/Parenteral/PO: C
Thông tin tư vấn bệnh nhân
This drug may cause blurred vision, dizziness or slight euphoria, if affected, do not drive or operate machinery.
Chỉ số theo dõi
If for prolonged use, monitor blood, urine, and LFTs.
Quá liều
Symptoms: Nausea, vomiting, flushing, dilated pupils, dry mouth and tongue, hot dry skin, fever, hypertension, sinus tachycardia, ataxia, nystagmus, drowsiness, delirium, agitation and visual hallucinations. Management: Administer activated charcoal or perform gastric lavage within 1 hour of ingestion. Establish patient airway and provide oxygen or ventilation to correct hypoxia or hypercapnia; administer intravascular volume expander or dopamine for hypo- or hyperthermia, hypotension; treat skin blisters as burns; administer diazepam for convulsions or delirium. Administer Na bicarbonate (even in the absence of acidosis) and correct hypoxia for cardiac dysrhythmias.
Tương tác
May enhance the sedative effect with other sedatives. May cause anxiety, confusion, tremors with propoxyphene. May increase the antimuscarinic effects with antihistamines, antispasmodics, TCAs, phenothiazines, dopaminergic antiparkinsonian drugs (e.g. amantadine), antiarrhythmics (e.g. disopyramide). Enhanced effect with anticholinergic drugs.
Tương tác với thức ăn
Alcohol may potentiate the CNS depressant effect of this drug.
Tác dụng
Description:
Mechanism of Action: Orphenadrine, a tertiary amine antimuscarinic, is an indirect skeletal muscle relaxant that is believed to work by central atropine-like effects. Additionally, it has weak antihistaminic and local anaesthetic properties.
Onset: 2-4 hours (oral).
Duration: 4-6 hours.
Pharmacokinetics:
Absorption: Readily absorbed from the gastrointestinal tract and after an IM inj.
Distribution: Rapidly distributed to tissues. Plasma protein binding: 20%
Metabolism: Extensively metabolised in the liver into approx 8 metabolites.
Excretion: Mainly via urine (8% as unchanged drug). Elimination half-life: 14-16 hours.
Đặc tính

Chemical Structure Image
Orphenadrine

Source: National Center for Biotechnology Information. PubChem Database. Orphenadrine, CID=4601, https://pubchem.ncbi.nlm.nih.gov/compound/Orphenadrine (accessed on Jan. 22, 2020)

Bảo quản
Store below 30°C. Protect from light, moisture, and heat.
Phân loại MIMS
Thuốc trị bệnh Parkinson / Thuốc giãn cơ
Phân loại ATC
N04AB02 - orphenadrine (chloride) ; Belongs to the class of anticholinergic agents, ethers chemically close to antihistamines. Used in the management of Parkinson's disease.
Tài liệu tham khảo
Anon. Orphenadrine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 27/05/2021.

Buckingham R (ed). Orphenadrine Citrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 27/05/2021.

iNova Pharmaceuticals (New Zealand) Limited. Norflex 100 mg Slow Release Tablets data sheet 11 December 2018. Medsafe. http://www.medsafe.govt.nz. Accessed 27/05/2021.

Joint Formulary Committee. Orphenadrine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 27/05/2021.

Norflex Tablet 100 mg (Adcock Ingram Ltd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 27/05/2021.

Orphenadrine Citrate Injection (A-S Medication Solutions). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 27/05/2021.

Orphenadrine Citrate Tablet, Extended Release (Bryant Ranch Prepack). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 27/05/2021.

Orphenadrine Hydrochloride 50 mg Tablets (Teva UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 27/05/2021.

Orphenadrine Hydrochloride 50 mg/5 mL Oral Solution (Rosemont Pharmaceuticals Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 27/05/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Orphenadrine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in